RTP Mobile Logo
Oncology Grand Rounds Series: Part 6 — Metastatic Lung Cancer (Webinar Video Proceedings)
Released July 2020

Proceedings from the sixth in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Ms Kelly EH Goodwin, Ms Wendi S Lee, Dr Suresh S Ramalingam and Dr Gregory J Riely. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this CNE (NCPD) activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with lung cancer.

    LEARNING OBJECTIVES

    • Recognize the incidence of genetic abnormalities commonly identified in patients with non-small cell lung cancer (NSCLC), and counsel patients regarding how these alterations may predict potential response (or lack thereof) to targeted therapy.
    • Review recent therapeutic advances related to the long-term clinical care of patients with NSCLC and an EGFR tumor mutation, and discern how this information should be applied in practice.
    • Assess other oncogenic signaling pathways (eg, ALK, ROS1, MET, RET) mediating the growth of tumors in unique subsets of patients, and recall published data with commercially available and experimental agents exploiting these targets.
    • Develop an understanding of the biologic basis for the investigation of immune checkpoint inhibitors for advanced NSCLC and small cell lung cancer (SCLC).
    • Appreciate available clinical trial data with and the current role of anti-PD-1/PD-L1 antibodies alone or in combination with chemotherapy and/or anti-angiogenic agents for patients with metastatic NSCLC.
    • Evaluate recently published clinical trial data with the use of an anti-PD-1/PD-L1 antibody in combination with etoposide/platinum chemotherapy as first-line treatment for extensive-stage SCLC, and identify patients appropriate for this novel approach.
    • Educate patients about the side effects associated with therapies commonly used in the management of lung cancer, and provide preventive strategies to reduce or ameliorate these toxicities.
    • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with NSCLC and SCLC to optimize clinical and quality-of-life outcomes.

    ACCREDITATION STATEMENT
    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    CREDIT DESIGNATION STATEMENTS
    Audio Program: This educational activity for 2.25 contact hours is provided by RTP during the period of August 2020 through August 2021.

    This activity is awarded 2.25 ANCC pharmacotherapeutic contact hours.

    Video Program: This educational activity for 1.5 contact hours is provided by RTP during the period of July 2020 through July 2021.

    This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE (NCPD) credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/Meetings/ONS2020/MetastaticLung/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for CNE (NCPD) accreditation. CNE (NCPD) programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE (NCPD) provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    Audio Program: To receive credit, participants should read the learning objectives and faculty disclosures, listen to the mp3s, review the downloadable slide sets, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSMetastaticLung2020/CNE. The corresponding video program is available as an alternative at ResearchToPractice.com/ONSMetastaticLung2020/Video.

    Video Program: To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSMetastaticLung2020/Video/CNE. The corresponding audio program is available as an alternative at ResearchToPractice.com/ONSMetastaticLung2020.

    CONTENT VALIDATION AND DISCLOSURES
    RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Kelly EH Goodwin, MSN, RN, ANP-BC
    Thoracic Cancer Center
    Massachusetts General Hospital
    Boston, Massachusetts

    No financial interests or affiliations to disclose.

    Wendi S Lee, MSN, RN, NP-C
    Department of Thoracic/Head and Neck Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreement: Pfizer Inc.

    Suresh S Ramalingam, MD
    Professor of Hematology and Medical Oncology
    Roberto C Goizueta Chair for Cancer Research
    Director, Division of Medical Oncology
    Deputy Director, Winship Cancer Institute
    Emory University School of Medicine
    Atlanta, Georgia

    Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Advaxis Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, Takeda Oncology, Tesaro, a GSK Company.

    Gregory J Riely, MD, PhD
    Associate Attending
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committee and Consulting Agreements: Daiichi Sankyo Inc, Takeda Oncology; Contracted Research: Merck, Mirati Therapeutics, Novartis, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

    RTP CNE (NCPD) PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.

    Audio release date: August 2020
    Audio expiration date: August 2021

    Video release date: July 2020
    Video expiration date: July 2021

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):